CTLA4 and melanoma: As a consequence, immunotherapy based on blocking co-inhibitory receptors such as CTLA-4 and PD-1 expressed on the T-lymphocyte surface has emerged as a powerful strategy in melanoma treatment with the development of several checkpoint blocking antibodies such as Ipilimumab or Pembrolizumab.